Market revenue in 2022 | USD 6,749.3 million |
Market revenue in 2030 | USD 12,874.0 million |
Growth rate | 8.4% (CAGR from 2022 to 2030) |
Largest segment | Immunoglobulins |
Fastest growing segment | Coagulation Factors |
Historical data covered | 2018 - 2021 |
Base year for estimation | 2022 |
Forecast period covered | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Albumin, Immunoglobulins, Coagulation Factors, Protease inhibitors, Others (thrombin, protein C, antithrombin) |
Key market players worldwide | Grifols SA Ordinary Shares - Class A, CSL Ltd, Takeda Pharmaceutical Co Ltd, Biotest AG ADR, Octapharma AG, Kedrion Biopharma, LFB (Laboratoire Français du Fractionnement et des Biotechnologies), Bio Products Laboratory, Intas Pharmaceuticals |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to plasma fractionation market will help companies and investors design strategic landscapes.
Immunoglobulins was the largest segment with a revenue share of 60.61% in 2022. Horizon Databook has segmented the Europe plasma fractionation market based on albumin, immunoglobulins, coagulation factors, protease inhibitors, others (thrombin, protein c, antithrombin) covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe plasma fractionation market , including forecasts for subscribers. This continent databook contains high-level insights into Europe plasma fractionation market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account